Wednesday, July 30, 2014

Three BT-featured CEOs sweep EY award finalist selections

Three BT-featured CEOs sweep EY award finalist selections

July 7, 2014 by · Leave a Comment 

Tweet All three finalists for the EY 2014 Ontario Entrepreneur of the Year award in the health sciences category have been featured in the past on BioTuesdays.com. They are Anthony Giovinazzo of Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH), Tom Reeves of closely held Interface Biologics and Dr. Arun Menawat of Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ). The Ontario winners will be announced […]

HCW starts Cesca Therapeutics at buy

HCW starts Cesca Therapeutics at buy

June 26, 2014 by · Leave a Comment 

Tweet H.C. Wainwright has launched coverage of Cesca Therapeutics (NASDAQ:KOOL) with a “buy” rating and a target price of $5, based on a combined discounted earnings per share and revenue multiple analysis and a comparable valuation methodology. The stock closed at $1.44 on Wednesday. Cesca’s core biotechnology franchise utilizes proprietary devices for the consistent processing, […]

Pivotal’s fight against fat gains media exposure

Pivotal’s fight against fat gains media exposure

June 25, 2014 by · Leave a Comment 

Tweet The latest issue of Bio Business magazine includes an article about the global obesity epidemic that highlights the efforts of Pivotal Therapeutics (OTCQX:PVTTF; CSE:PVO) to tackle the problem by focusing on the development of Omega-3 therapies and diagnostics. “The consequences of an Omega-3 deficiency could be obesity, diabetes, elevated triglycerides, high cholesterol and coronary heart […]

Stifel ups Aerie Pharma price target to $33

Stifel ups Aerie Pharma price target to $33

June 25, 2014 by · Leave a Comment 

Tweet Stifel has raised its price target for “buy-rated” Aerie Pharmaceuticals (NASDAQ:AERI) to $33 from $24 after the company released important Phase 2b data for Roclatan, its once-daily quadruple-action glaucoma treatment, “achieving all study endpoints with statistical and clinical relevance over its components (Rhopressa and latanoprost). Shares of Aerie touched a 52-week high of $29.91 […]

diaDexus makes management changes

diaDexus makes management changes

June 25, 2014 by · Leave a Comment 

Tweet Brian Ward will retire as CEO and a director of diaDexus(OTCQB:DDXS) by the end of 2014, and Alexander Johnson has been named president, effective Aug. 4. Mr. Johnson was previously with Novartis from 2009 to 2014 in a series of roles of increasing responsibility, most recently as director of M&A based in the company’s […]

Ciclofilin developing first drug for HCV/HIV-1 co-infection

Ciclofilin developing first drug for HCV/HIV-1 co-infection

June 24, 2014 by · Leave a Comment 

Tweet Closely held Ciclofilin Pharmaceuticals is developing what, it hopes, will be the first clinically effective treatment for hepatitis C virus (HCV)/HIV-1 co-infection, with specific antiviral activity directed against both viruses. “Other companies are working on one or the other virus, so we would like to position ourselves as the company working on co-infection, where […]

HCW expands biotech practice with four hires

HCW expands biotech practice with four hires

June 20, 2014 by · Leave a Comment 

Tweet H.C. Wainwright & Co has hired one managing director in equity research and three VPs in investment banking to further enhance its biotechnology practice. Swayampakula Ramakanth (“RK”) has joined HCW in equity research as managing director, senior biotechnology analyst.  Prior to joining HCW, Dr. Ramakanth was an analyst at Jefferies and Merrill Lynch, covering […]

Canaccord upgrades AngioDynamics to buy

Canaccord upgrades AngioDynamics to buy

June 19, 2014 by · Leave a Comment 

Tweet Canaccord Genuity has upgraded AngioDynamics (NASDAQ:ANGO) to “buy” from “hold” and raised its 12-month price target to $20 from $16.25 after the company received FDA approval for the Celerity tip location system. The stock closed at $15.31 on Wednesday. “We believe improving business trends and strong cash generation will drive growth over the next […]

Analysts start Agile Therapeutics at buy, outperform

Analysts start Agile Therapeutics at buy, outperform

June 17, 2014 by · Leave a Comment 

Tweet Janney Capital Markets, Cantor Fitzgerald and William Blair have launched coverage of Agile Therapeutics (NASDAQ:AGRX) at “buy” and “outperform” ratings. Janney analyst Kimberly Lee writes that the company’s combined hormonal contraceptive (CHC) patch, Twirla, “should improve patient compliance and provide efficacy and safety similar to low-dose oral contraceptives while targeting an unmet need for […]

Trillium eyeing pre-IND meeting in third quarter

Trillium eyeing pre-IND meeting in third quarter

June 17, 2014 by · Leave a Comment 

Tweet Trillium Therapeutics (TSX:TR; OTCQX:SCTPF) hopes to have a pre-IND meeting with the FDA in the second half of this year and begin clinical testing of its lead biologic cancer immunotherapy, SIRPαFc, for the treatment of acute myeloid leukaemia (AML) in the second half of 2015. “There is strong evidence that AML is sustained by leukemia […]

Next Page »

Email Newsletters with Constant Contact
Google+